Board of Directors, Scientific Board and Management


Dr. Steven Boyages

M.D., MB, BS, Ph.D
Chairman of the Board (Independent)
A practicing clinician in endocrinology with more than 30 years’ experience in medicine, including multiple executive positions, Dr. Steven Boyages serves as Chairman of the Board of GBS Inc. 

Dr. Boyages previously held the position of Chief Executive of the Sydney West Area Health Service (SWAHS), which is now known as Western Sydney Local Health District. Covering a population of 1.2 million people, SWAHS employed more than 15,000 staff and had a gross operating budget of $2 billion (AUD), managing $1.6 billion (AUD) worth of assets. Dr. Boyages has also served as Medical Director for eHealth New South Wales, and was the foundation Chief Executive of the Clinical Education and Training Institute (CETI) New South Wales (NSW), Australia, set up to ensure the development and the delivery of clinical education and training across the NSW public health system. Previous to this, Dr. Boyages was the Director of Diabetes and Endocrinology at Westmead Hospital, from 1990 to 1999. During this time, Dr. Boyages’ major achievements were to define the pathophysiology of thyroid hormone deficiency on brain development secondary to iodine deficiency; to develop prevention strategies in iodine deficient communities in China, India, Indonesia and Northern Italy; to define the impact of growth hormone excess and deficiency in adults and to develop innovative population health models of care for people with diabetes. Dr. Boyages continues an active research career in a range of fields, but mostly in the pursuit of better models of chronic disease prevention and management. 

Following this position, Dr. Boyages was the foundation director of the Centre for Research and Clinical Policy in NSW Health in 1999, during which he established the Priority Health Programs (receiving $15 million (AUD) in funding per annum), doubled the Research Infrastructure Grants Program, established the Quality Branch of NSW Health and was appointed as Clinical Advisor to the Director General to implement the Government Action Plan for Health Reform. Additionally, Dr. Boyages was instrumental in establishing and securing funding for the NSW biotechnology strategy, BioFirst, a $150 (AUD) million investment. 

Mr. Harry Simeonidis

CEO, President and Director
Mr. Simeonidis has more than 25 years’ experience in global executive management positions in healthcare, pharmaceutical and life sciences businesses. His previous roles include CEO of Australia and New Zealand at GE Healthcare and, more recently, General Manager for Surgery Asia Pacific at GE Healthcare. Mr Simeonidis also serves as Non-Executive Director of FarmaForce, a member company of The iQ Group Global.

Dr. George Syrmalis

M.D., Ph.D, MACNP, MAAPP
Scientific Board Member
Dr. Syrmalis is trained in Nuclear Medicine-radiation immunology and established The iQ Group Global Ltd. (formerly iQnovate) in 2011. Previously, Dr. Syrmalis founded and led as CEO and Chairman The Bionuclear Group SA, (1995-2005) incorporating Antisoma SA, Bionuclear Institute of Diagnosis and Therapy SA, Bionuclear Research and Development SA and Vitalcheck SA. He developed a business model by addressing unmet clinical needs and leveraging on synergies between Bionuclear Group companies.
• Antisoma SA: focused on development of novel biologic compounds both radio diagnostic and radio therapeutic in the area of oncology.
• Bionuclear Institute for Diagnosis and Therapy SA: expanded into medical centers-renal dialysis clinics and the development of Europe’s most prominent reference pathology service.
• Bionuclear Research and Development SA: novel and generic radiopharmaceutical production.
• Vitalcheck SA: Research, development and commercialization of point of care tests for professional and layman use. From 2005 onwards George continued his career as advisor to the Biopharmaceutical industry, advising on translational clinical trials, biomarkers and strategy to commercialize novel biologic entities in the areas of oncology, epilepsy and autoimmune diseases. 

Mr. Spiro Sakiris

B.Bus, Dip Law, CA
Chief Financial Officer
Mr. Sakiris has 32 years’ experience in accounting and taxation, IPOs and capital raising, and business system designs, including the application of IFRS and US GAAP for the life science industry. Mr. Sakiris is a member of the Institute of Chartered Accountants of Australia & New Zealand, a registered Series 28 principal with iQ Capital (USA) LLC and a registered broker-dealer with FINRA. He also serves as Special Projects Lead at The iQ Group Global.

Professor Paul Dastoor

Ph.D, B.A. (Hons)
Scientific Board Member
Prof. Dastoor is a Professor in Physics in the School of Mathematical and Physical Sciences and the Director of the Priority Research Centre for Organic Electronics at the University of Newcastle in Australia. He received his B.A. degree in Natural Sciences from the University of Cambridge in 1990 and his Ph.D. in Surface Physics, also from the University of Cambridge, in 1995. 
Prof. Dastoor’s expertise covers surface analysis, electron spectroscopy, thin film growth, organic electronics, organosilane chemistry, polymer films, atom beam optics and microscopy and medical devices. His research can be grouped in three main areas: (1) Helium Atom Microscopy, (2) Polymer Adsorption on Metal Surfaces and (3) Organic Electronic Devices. Helium Atom Microscopy Atomic scattering from surfaces has matured into a unique analytical technique for the study of formation of thin film structures.

Professor Jonathan Sessler

Ph.D. (Pharmacology)
Director (Independent)
Prof. Sessler has been a member of the Board of Directors since November 2019. As a chemistry scientist, Prof. Sessler is well known for his ground-breaking work on expanded porphyrins and their applications to biology and medicine. Obtaining a Bachelor of Science in Chemistry with Highest Honors from The University of California, Berkeley, Prof. Sessler went on to complete his Ph.D. in Organic Chemistry at Stanford University in 1982. Since 1984, Prof. Sessler has been a Professor of Chemistry at The University of Texas Austin, one of the world’s leading basic and applied research facilities, and currently holds The Doherty-Welch Chair. He has received many awards and recognitions throughout his career. In 1991 he co-founded Pharmacyclics, a pharmaceutical research company previously listed on Nasdaq.  


Lawrence Fisher

Member, Audit Committee (Independent)
A securities lawyer in New York City for more than 40 years, Lawrence is a graduate of Columbia College and Columbia University Law School, and a Research Fellow of the London School of Economics. Lawrence has extensive experience representing public companies and investment banking firms in connection with Initial Public Offerings. During his career, Mr. Fisher was a partner at Orrick, Herrington & Sutcliffe law firm for 11 years, at Kelley, Drye & Warren lawfirm for 10 years, and Parker, Chapin & Flattau, serving on all firms’ Executive Committees. Lawrence has held various Board positions, including Financial Federal Corporation (NYSE), National Bank of New York City and Viking Energy Group. Mr. Fisher brings to the Board his vast experience as a lawyer in the field of capital markets.


Christopher Towers

BSc, CPA
Chair, Audit Committee (Independent)
A Certified Public Accountant with 12 years’ experience in auditing, accounting, and financial reporting in previous roles held at PricewaterhouseCoopers and Pall Corporation, Mr. Towers chairs the Audit Committee for GBS Inc. Mr. Towers is EVP, Chief Accounting Officer and Principal Financial Officer of Newtek Business Services Corp (NASDAQ:NEWT). His expertise includes auditing, SEC reporting, US GAAP, experience in leading equity and debt raisings, due diligence on business mergers and acquisitions, SOX compliance, FP&A, treasury, and tax. He holds a Bachelor of Science from Hofstra University and is a member of the American Institute of Certified Public Accountants. Mr. Towers brings to the Board expertise in financial reporting to capital markets and an understanding of compliance and the audit process.

Dr. Tom Parmakellis

MBBS
Director (Independent)
Dr. Tom Parmakellis has 25 years’ experience as a medical practitioner. Having negotiated exclusive distribution rights for internationally recognized medical lasers in Australia, Dr. Parmakellis’s experience in healthcare markets reaches back to 1996 when he introduced laser hair removal into the Australian market.

In 2009, Dr. Parmakellis founded Lookfresh Cosmestic Medicine, which he still owns today, and in 2017 he founded SkinLift Ultherapy.

Dr. Parmakellis holds a MBBS from the University of Sydney, is a fellow of the Royal Australian College of General Practitioners (FRACGP) and a fellow of the Cosmetic Physicians College Australasia (FCPCA).

Mr. Jonathan Hurd

CAMS
Director (Independent)
Mr. Hurd has been a member of the GBS Inc. Board of Directors since April 2018, serving as our Chairman of the Board from August 2018 to November 2019. Mr. Hurd has expertise in broker-dealer and investment advisory regulations and is experienced in FINRA and SEC rules and regulations. Mr. Hurd has served as Founder and CEO at Asgard Regulatory Group, or “Asgard,” since founding the firm in 2008. Mr. Hurd was also a Supervisor of Examiners at FINRA, previously NASD, in the New York District Office. While with FINRA, he supervised routine examinations of FINRA member firms, and conducted large-scale enforcement cases jointly with the Justice Department and Federal Bureau of Investigations. Mr. Hurd is also a Certified Anti-Money Laundering Specialist (CAMS) and holds the Series 7, 24, 27, 53, 55, 63, 66, 79 and 99 licenses as well as his NYS Life and Health Insurance licenses.

Ms. Victoria Gavrilenko

Operations Manager and Director
Ms. Gavrilenko is responsible for the coordination of GBS Inc. activities within the US as well as overseas business partners and contractors. 

Dr. George Margelis

MBBS
Director (Independent)
Dr. Margelis is a medical practitioner with 30 years’ experience. Dr. Margelis was Chief Information Officer of Macquarie Health Corporation where he led a team producing online health applications. He has worked at Intel and the Intel-GE Innovation spin-off and was also senior adviser to HIMSS, the international peak body for health technology. Dr. Margelis is currently Adjunct Associate Professor at the University of Western Sydney with the TeleHealth Research & Innovation Laboratory (THRIL) and a member of Ignition Labs. 

Mr. Leon Kempler

AM
Director (Independent)
Mr. Kempler is a highly experienced business leader of the APAC region. Formally recognized in his field, Mr Kempler received the Medal of Order from the Governor General in both 1998 and 2018, recognizing his services to Australia’s international business relations and contribution to Australia’s development in culture, education, and medicine.

With more than 30 years’ experience, Mr Kempler’s honorary roles have included Chairman of the Advisory Council of the National Science and Technology Centre – Questacon; and National Chairman of the Australia-Israel Chamber of Commerce, among many others. 

Sign Up

Register for email alerts for the latest on the Biosensor Platform and GBS Inc.

  • This field is for validation purposes and should be left unchanged.